양성 전립선 비대증 치료 시장 규모, 점유율, 동향 및 예측 : 치료법별, 지역별(2026-2034년)

The global benign prostatic hyperplasia treatment market size was valued at USD 13.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 18.9 Billion by 2034, exhibiting a CAGR of 4.09% during 2026-2034. North America currently dominates the market, holding a significant share of over 34.8% in 2025 . The market is driven by the rising prevalence of BPH among aging men, advancements in minimally invasive procedures, and improved drug formulations. Innovations in laser therapies and combination treatments further enhance patient outcomes, increasing the benign prostatic hyperplasia treatment market share.

Key drivers in the benign prostatic hyperplasia (BPH) treatment market are the increasing prevalence of BPH among the aging male population, increasing awareness of urological health, and advances in minimally invasive treatment options. The demand for effective therapies is growing due to the impact of BPH on quality of life including urinary symptoms and complications. Innovations including laser therapy improved drug formulation and combinations also enhance growth in the market along with a rise in healthcare access as well as favorable reimbursement policies in developed regions. For instance, in September 2024, Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for benign prostate enlargement a condition affecting about 50% of men over 50. Funded by the Prostate Project charity, this minimally invasive procedure allows rapid recovery and minimal side effects improving patient quality of life and reducing hospital stays. These advancements are creating a positive benign prostatic hyperplasia treatment market outlook.

The key drivers of the United States benign prostatic hyperplasia (BPH) treatment market are a high prevalence of BPH among the aging male population and increased awareness of urological health. Advances in minimally invasive procedures such as laser-based therapies and prostatic artery embolization also gained popularity based on their efficiency and quicker recovery times. For instance, in July 2023, Adventist Health Portland launched Aquablation Therapy a minimally invasive treatment for benign prostatic hyperplasia (BPH) using water and robotic precision. This innovative procedure represents a new option for men dealing with enlarged prostate symptoms. There is also availability of improved medications and combination therapies which boost the range of treatment options. This further represents one of the key benign prostatic hyperplasia treatment market trends in the United States.

BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET TRENDS:

Shift Toward Minimally Invasive Procedures

Minimally invasive procedures are being increasingly used for the treatment of benign prostatic hyperplasia. According to the U.S. National Institutes of Health (NIH), an estimated 30% of men with moderate to severe BPH symptoms undergo some form of minimally invasive treatment. Techniques include laser therapy, TUMT, and TURP. These are well accepted by both patients and physicians because they have been proven effective with minimal recovery time. Such procedures ensure the treatment is targeted with minimal damage to the surrounding tissues and, therefore, fewer complications in the form of bleeding or infection. In addition, the patients face less pain and faster return to regular activities than the traditional open surgeries. This is in tune with the general trends in the healthcare sector toward less invasive outpatient-focused services. Growth of technologies like Holmium laser enucleation and GreenLight laser therapy further fueled the shifting market, to the extent that, nowadays, alternatives are offered to the patients who do not want to undergo long durations of hospitalization or an invasive surgery. The growing acceptance of these procedures will lead to increased benign prostatic hyperplasia treatment market demand over the time.

Emergence of Advanced Drug Therapies

The landscape of BPH treatment is undergoing a sea change with the emergence of new pharmacological therapies. New classes of drugs and combination therapies aim at better symptom management with fewer side effects. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 50% of men aged 51 to 60, and up to 90% of men over the age of 80, are affected by BPH, leading to a growing need for pharmacological treatment options. While traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors continue to play their role, advanced drug therapies, such as alpha-blockers and 5-ARIs, are common treatments but come with notable side effects like dizziness and sexual dysfunction. The expiration of patents for drugs like Avodart and Cialis has opened opportunities for generics, providing affordable alternatives and driving market growth in drug treatments. Efforts are increasing to develop drugs like PDE5 inhibitors and novel dual-target therapies offer a more holistic approach to symptom relief. These advanced drugs treat not only the prostate but also erectile dysfunction, a common comorbidity for BPH. With more treatments available, these patients can take advantage of an individualized, symptom-based plan that is better suited to his or her health conditions and symptoms. Yet another trend to be seen includes combining existing medicines to improve potency and minimize harmful side effects. The landscape for BPH is set to change even more dramatically with the entry of biologics and gene therapies into clinical trials, providing the patient with effective long-term treatment.

Rising Geriatric Population

The global geriatric population is a major growth driver for the BPH treatment market. As people age, the incidence of BPH increases, and the condition is most common in men over the age of 50. From 1974 to 2024, the global proportion of individuals aged 65 nearly doubled, rising from 5.5% to 10.3%. From 2024 to 2074, the figure is set to double once more, reaching 20.7%, as per United Nations demographic estimates. At the same time, the population of individuals aged 80 and older is expected to exceed three times its current size. The elderly population is expected to increase substantially in developed regions, thus significantly expanding the pool of people requiring treatment for BPH. This demographic change is likely to further stress healthcare systems by demanding effective yet affordable treatment interventions. An aging global population is fueling demand for BPH treatments, with generics offering lower-cost options that increase patient access and overall treatment sales. Older males are more predisposed to co-morbidities like hypertension and diabetes. Such comorbidities further complicate the management of BPH, thus resulting in a driving force for tailormade regimens that meet multiple health demands at one time. Older adults are more vulnerable to side effects from BPH treatments, including dizziness and an increased risk of falls. With an aging population, minimizing these risks through safer treatments is becoming a priority in healthcare. Pharmaceutical and healthcare companies, therefore, have been developing drugs that treat the symptoms of BPH and generally enhance the quality of life for patients, especially the elderly. The aging population is projected to continue increasing and influence the market by enhancing the demand for pharmacological as well as surgical treatment options.

BENIGN PROSTATIC HYPERPLASIA TREATMENT INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

• Drug Class
  • Alpha-Blockers
  • 5-Alpha-reductase Inhibitors (5-ARIs)
  • Phosphodiesterase-5 Enzyme Inhibitors
  • Others
• Minimally Invasive Surgeries
  • Transurethral Resection of the Prostate (TURP)
  • Transurethral Incision of the Prostate (TUIP)
  • Transurethral Microwave Thermotherapy (TUMT)
  • Robotic Surgeries
  • Prostatic Urethral Lifts
  • Others
• Laser Therapy

Alpha-blockers account for the highest market benign prostatic hyperplasia treatment market share of the drug class category in BPH treatment. They are potent in offering symptomatic relief as quickly as possible. They are able to relax the muscles within the prostate and bladder neck to facilitate urine flow and reduce obstruction. Alpha-blockers are first-line drugs used for BPH due to their efficacy, availability and fewer side effects. Their ability to treat lower urinary tract symptoms without significantly altering prostate size makes them highly preferred by physicians. Increasing awareness, a growing aging male population and advancements in drug formulations further bolster the dominance of alpha-blockers in the BPH treatment market.

Regional Analysis:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

In 2025, North America accounted for the largest market share of over 34.8%. North America is the most significant market of BPH treatments mainly driven by the sophisticated healthcare infrastructure within the region and the high incidence of BPH among aging males along with better awareness about urological health. The United States is a notable contributor to the market due to its large population of geriatrics and the use of advanced medical treatments which include minimally invasive procedures as well as newer drug therapies. Favorable reimbursement policies along with cutting-edge technologies like robotic-assisted surgeries and laser therapies continue to support benign prostatic hyperplasia treatment market growth. The key pharmaceutical and medical device manufacturers located in the region also stimulate continuous innovation. The growing importance of early diagnosis and proactive management of BPH symptoms further enhance North America's position as a global leader in the BPH treatment market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

In 2025, the United States captured 85.00% of revenue in the North American market. The U.S. BPH market is increasing due to a growing aging male population and the rising awareness of treatment options. According to the American Urological Association, about 50% of men over 50 years old have BPH or an enlarged prostate. Prevalence of BPH rises with age and, among men aged 60 to 69 years, it reaches 70% and among those over 70 years, 80%. Growth drivers are major effective medical therapies like 5-alpha reductase inhibitors and alpha blockers along with increasing surgical procedure adoption. Market growth is further facilitated by a shift towards telemedicine and home-based treatments that ensure broader accessibility to care. This market is, therefore attracting more prominent players like AbbVie and Astellas into their portfolios by focusing on innovation and patient-centric approaches.

EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

The BPH market in the region is rapidly growing due to an aging population and the increasing prevalence of prostate enlargement. The European Association of Urology states that benign prostatic hyperplasia, or BPH, affects 50% of men over the age of 50, while the condition progresses with age and reaches 70% in the age group 60 to 69 and 80% above 70. The awareness about BPH symptoms and the high number of new diagnoses are main drivers for this market growth. In Germany, the UK, and France, among others, they are widely accepting advanced treatments with surgical minimally invasive approaches, drug therapies, and combination therapies where better management could be achieved for patients. Boehringer Ingelheim and Janssen, the two leading pharmaceutical giants, lead in innovating by introducing new drug formulations that meet unmet needs in BPH care. Additionally, telehealth solutions are picking up the pace in offering consultation and allowing for an early diagnosis that would be a driving factor in this European market growth.

ASIA PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

The Asia Pacific BPH market is growing rapidly because of the increasing awareness, aging male population, and improved access to healthcare. Asian Development Bank says, by 2050, one in four people in Asia and the Pacific will be over 60 years of age. Projections indicate that this demographic shift, where the population of older persons aged over 60 in the region is expected to triple from 2010 until 2050, will attain nearly 1.3 billion. This demographic shift will create a significant demand for BPH treatments as well, given the rising prevalence of BPH with age. According to an industry report, the market size for BPH was USD 1.8 billion in 2023 in this region, primarily driven by an escalating diagnosis rate and government initiatives to enhance the healthcare system in these countries. The main momentum-setters in this region are Japan, South Korea, and China, with the state-of-the-art advancements in BPH treatment technology, including robotic surgeries and novel pharmacological interventions. Herbal and traditional treatments are also gaining relevance more in the region, mainly in the Indian subcontinent.

LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

Latin American BPH is experiencing a rising tide, mainly fueled by the rise in the population's aging demographic and the resultant increase in the need for effective treatment. According to the Pan American Health Organization (PAHO), 20% of men older than 50 years in this region suffer from BPH. In addition, there is a demand for BPH-related treatments within Brazil and Mexico. BPH progresses with age in a majority of Latin American male populations. Cancer of the prostate is the highest form of any cancer among male patients in Brazil and most cases, in fact, point to BPH. More recently, increased vigilance on symptomatic manifestations encourages men to search for treatments or even pharmaceutical-based and minimally invasive surgical treatments. Access to health care in Brazil and Mexico, for example, is expanding further, creating more room for market expansion. Local pharmaceutical firms and multinational players are also taking advantage of this trend to present a myriad of treatment options specific to the regional market.

MIDDLE EAST AND AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET

The BPH market in the Middle East and Africa is set to grow based on the area's increasing aging population and growing attention to prostate care. According to the NIH, the prevalence rate of BPH in the Middle East ranges between 13.84% to 23.79%. In this regard, the variation was due to some demographic factors across the region in addition to differing access to care. As the male population aged above 50 continues to climb, BPH treatments remain in demand. Improving healthcare regimes in the form of better diagnosis rates are being recorded in Saudi Arabia and South Africa. Local players have scaled up their activities both on the medical and the surgical side, while international pharmaceutical majors have positioned themselves in the market. Increased attention on BPH management in both the public and private sectors is expected to spur major growth in the market over the next few years.

COMPETITIVE LANDSCAPE:

The benign prostatic hyperplasia (BPH) treatment market is highly competitive with numerous pharmaceutical and medical device companies offering a wide range of solutions from medications to minimally invasive procedures. Companies are focusing on innovation such as developing advanced drug formulations with improved efficacy and fewer side effects as well as refining minimally invasive techniques like laser therapies and robotic-assisted surgeries. The market is also seeing significant investment in clinical trials and the development of combination therapies to enhance treatment outcomes. Strategic partnerships, mergers and acquisitions are common enabling companies to expand their product portfolios and geographic reach.

The report provides a comprehensive analysis of the competitive landscape in the benign prostatic hyperplasia treatment market with detailed profiles of all major companies, including:

• Abbott Laboratories
• Allergan Plc (AbbVie Inc.)
• Asahi Kasei Corporation
• Astellas Pharma Inc.
• Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
• Boston Scientific Corporation
• GlaxoSmithKline Plc
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the benign prostatic hyperplasia treatment market?

2. What are the market drivers for benign prostatic hyperplasia (BHP) treatment devices?

3. What is the benign prostatic hyperplasia (BPH) treatment device market growth?

4. What are the key factors driving the benign prostatic hyperplasia treatment market?

5. Which region accounts for the largest benign prostatic hyperplasia treatment market share?

6. Which are the leading companies in the global benign prostatic hyperplasia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Treatment Type

• 6.1 Drug Class
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Alpha-Blockers
    • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
    • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Minimally Invasive Surgeries
  • 6.2.1 Market Trends
  • 6.2.2 Major Types
    • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
    • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
    • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
    • 6.2.2.4 Robotic Surgeries
    • 6.2.2.5 Prostatic Urethral Lifts
    • 6.2.2.6 Others
  • 6.2.3 Market Forecast
• 6.3 Laser Therapy
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Region

• 7.1 North America
  • 7.1.1 United States
    • 7.1.1.1 Market Trends
    • 7.1.1.2 Market Forecast
  • 7.1.2 Canada
    • 7.1.2.1 Market Trends
    • 7.1.2.2 Market Forecast
• 7.2 Asia Pacific
  • 7.2.1 China
    • 7.2.1.1 Market Trends
    • 7.2.1.2 Market Forecast
  • 7.2.2 Japan
    • 7.2.2.1 Market Trends
    • 7.2.2.2 Market Forecast
  • 7.2.3 India
    • 7.2.3.1 Market Trends
    • 7.2.3.2 Market Forecast
  • 7.2.4 South Korea
    • 7.2.4.1 Market Trends
    • 7.2.4.2 Market Forecast
  • 7.2.5 Australia
    • 7.2.5.1 Market Trends
    • 7.2.5.2 Market Forecast
  • 7.2.6 Indonesia
    • 7.2.6.1 Market Trends
    • 7.2.6.2 Market Forecast
  • 7.2.7 Others
    • 7.2.7.1 Market Trends
    • 7.2.7.2 Market Forecast
• 7.3 Europe
  • 7.3.1 Germany
    • 7.3.1.1 Market Trends
    • 7.3.1.2 Market Forecast
  • 7.3.2 France
    • 7.3.2.1 Market Trends
    • 7.3.2.2 Market Forecast
  • 7.3.3 United Kingdom
    • 7.3.3.1 Market Trends
    • 7.3.3.2 Market Forecast
  • 7.3.4 Italy
    • 7.3.4.1 Market Trends
    • 7.3.4.2 Market Forecast
  • 7.3.5 Spain
    • 7.3.5.1 Market Trends
    • 7.3.5.2 Market Forecast
  • 7.3.6 Russia
    • 7.3.6.1 Market Trends
    • 7.3.6.2 Market Forecast
  • 7.3.7 Others
    • 7.3.7.1 Market Trends
    • 7.3.7.2 Market Forecast
• 7.4 Latin America
  • 7.4.1 Brazil
    • 7.4.1.1 Market Trends
    • 7.4.1.2 Market Forecast
  • 7.4.2 Mexico
    • 7.4.2.1 Market Trends
    • 7.4.2.2 Market Forecast
  • 7.4.3 Others
    • 7.4.3.1 Market Trends
    • 7.4.3.2 Market Forecast
• 7.5 Middle East and Africa
  • 7.5.1 Market Trends
  • 7.5.2 Market Breakup by Country
  • 7.5.3 Market Forecast

8 SWOT Analysis

• 8.1 Overview
• 8.2 Strengths
• 8.3 Weaknesses
• 8.4 Opportunities
• 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

• 10.1 Overview
• 10.2 Bargaining Power of Buyers
• 10.3 Bargaining Power of Suppliers
• 10.4 Degree of Competition
• 10.5 Threat of New Entrants
• 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

• 12.1 Market Structure
• 12.2 Key Players
• 12.3 Profiles of Key Players
  • 12.3.1 Abbott Laboratories
    • 12.3.1.1 Company Overview
    • 12.3.1.2 Product Portfolio
    • 12.3.1.3 Financials
    • 12.3.1.4 SWOT Analysis
  • 12.3.2 Allergan plc (AbbVie Inc.)
    • 12.3.2.1 Company Overview
    • 12.3.2.2 Product Portfolio
    • 12.3.2.3 Financials
    • 12.3.2.4 SWOT Analysis
  • 12.3.3 Asahi Kasei Corporation
    • 12.3.3.1 Company Overview
    • 12.3.3.2 Product Portfolio
    • 12.3.3.3 Financials
    • 12.3.3.4 SWOT Analysis
  • 12.3.4 Astellas Pharma Inc.
    • 12.3.4.1 Company Overview
    • 12.3.4.2 Product Portfolio
    • 12.3.4.3 Financials
    • 12.3.4.4 SWOT Analysis
  • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
    • 12.3.5.1 Company Overview
    • 12.3.5.2 Product Portfolio
    • 12.3.5.3 SWOT Analysis
  • 12.3.6 Boston Scientific Corporation
    • 12.3.6.1 Company Overview
    • 12.3.6.2 Product Portfolio
    • 12.3.6.3 Financials
    • 12.3.6.4 SWOT Analysis
  • 12.3.7 GlaxoSmithKline Plc
    • 12.3.7.1 Company Overview
    • 12.3.7.2 Product Portfolio
    • 12.3.7.3 Financials
    • 12.3.7.4 SWOT Analysis
  • 12.3.8 Pfizer Inc.
    • 12.3.8.1 Company Overview
    • 12.3.8.2 Product Portfolio
    • 12.3.8.3 Financials
    • 12.3.8.4 SWOT Analysis
  • 12.3.9 Sanofi S.A.
    • 12.3.9.1 Company Overview
    • 12.3.9.2 Product Portfolio
    • 12.3.9.3 Financials
    • 12.3.9.4 SWOT Analysis
  • 12.3.10 Teva Pharmaceutical Industries Ltd.
    • 12.3.10.1 Company Overview
    • 12.3.10.2 Product Portfolio
    • 12.3.10.3 Financials
    • 12.3.10.4 SWOT Analysis